Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally.
The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next …

Background Three-dose regimens for human papillomavirus (HPV) vaccines are expensive
and difficult to complete, especially in settings where the need for cervical cancer prevention …

Human papillomavirus (HPV) is causally associated with 5% of cancers, including cancers
of the cervix, penis, vulva, vagina, anus and oropharynx. The most carcinogenic HPV is HPV …

Human papillomavirus (HPV) types cause approximately 70% of cervical cancer worldwide.
Two vaccines have been recently evaluated in randomized controlled trials: the bivalent …

Background The objective of this study was to determine whether the 3-dose quadrivalent
human papillomavirus (HPV) vaccine series (HPV-6,-11,-16,-18) is immunogenic and safe in …

Background Vulval and vaginal cancers among younger women are often related to
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …

Early data from randomized controlled trials consistently show that prophylactic human
papillomavirus virus-like particle (HPV VLP) vaccines are effective in preventing infection …

In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent
vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also …

Background The authors investigated the durability of vaccine efficacy (VE) against human
papillomavirus (HPV) 16 or 18 infections and antibody response among nonrandomly …

Abstract Background Human papillomavirus (HPV)–6/11/16/18 vaccine reduces the risk of
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …